Gwathmey

Rosalie Dunn, Ph.D., has joined Gwathmey, a preclinical CRO, as chief executive officer. Dr. Dunn has more than 28 years of experience working with small businesses and the federal government. Prior to joining Gwathmey, Dr. Dunn managed multimillion dollar portfolios for the National Institutes of Health (NIH), including cardiovascular devices and technologies, clinical studies, imaging applications, development of new animal models, bioengineering projects, sleep research, computer models, atherosclerotic plaque detection and classification, antiarrhythmic treatments and devices, telemetry systems and device miniaturization.

While at the NIH she was Senior Scientific Administrator with the National Heart, Lung and Blood Institute (NHLBI). Dr. Dunn has held NIH-wide responsibility for developing, planning and managing small business programs. She received multiple NIH Awards of Merit as well as a Congressional Commendation for helping small businesses thrive.

Dr. Dunn remarked, “This difficult economy challenges smaller biotechnology as well as larger pharmaceutical companies, but at the same time it provides unique opportunities to forge new interrelationships that capitalize on niche expertise. In this case Gwathmey Inc. is in a prime position to provide individualized service economically and quickly. This is especially prominent in the cardiovascular and heart failure research area, as documented by Dr. Gwathmey’s continued research supported by the NIH and her publications in medical research journals. It is my job to expand our strategic relationships and pursue new business initiatives for medical drug, treatment and device testing with a special emphasis in cardiovascular applications.”